{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T12:44:11Z","timestamp":1784292251331,"version":"3.55.0"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a rare and highly aggressive ovarian neoplasm, predominantly affecting young women, often in their second or third decade of life. Despite its distinctive clinical and pathological features, diagnosis is frequently delayed due to overlapping characteristics with other small round blue cell tumors. A hallmark of SCCOHT is the biallelic inactivation of the SMARCA4 gene, which leads to loss of BRG1 protein expression and disrupts epigenetic regulation via the SWI\/SNF chromatin-remodeling complex. Unlike many other malignancies, SCCOHT exhibits low mutational burden and diploid karyotype, suggesting that epigenetic dysregulation, rather than genomic instability, is the underlying oncogenic mechanism. Clinically, SCCOHT often presents with nonspecific abdominal or pelvic symptoms and is uniquely associated with paraneoplastic hypercalcemia in up to two-thirds of cases. Diagnosis requires a combination of imaging, laboratory evaluation, histopathology, and immunohistochemistry. Treatment is not standardized but typically involves a multimodal approach, including radical surgery and platinum-based chemotherapy, often with multi-agent regimens. The role of radiotherapy is less well defined but may be considered for local control or palliation. Prognosis remains poor, with high recurrence rates and limited response to salvage therapy. Emerging molecular insights have prompted investigations into targeted therapies and immunotherapy, though clinical data are limited. Given the frequent presence of germline SMARCA4 mutations, genetic counseling is strongly recommended, and ongoing research is essential to improve diagnostic accuracy, personalize treatment, and enhance outcomes for this devastating malignancy.<\/jats:p>","DOI":"10.3389\/fonc.2025.1645361","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T04:10:14Z","timestamp":1755231014000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Small cell carcinoma of the ovary, hypercalcemic type: a mini review"],"prefix":"10.3389","volume":"15","author":[{"given":"Marta","family":"Tripepi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana G.","family":"da Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis S.","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Casanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19820101)49:1<188::aid-cncr2820490137>3.0.co;2-d","article-title":"Small cell carcinoma of the ovary with hypercalcemia: a report of eleven cases","volume":"49","author":"Dickersin","year":"1982","journal-title":"Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199411000-00004","article-title":"Small cell carcinoma of the ovary, hypercalcemic type. A clinicopathological analysis of 150 cases","volume":"18","author":"Young RH","year":"1994","journal-title":"Am J Surg Pathology"},{"key":"B3","volume-title":"World Health Organisation Classification of Tumours of the Female Reproductive Organs","author":"Kurman","year":"2014"},{"key":"B4","doi-asserted-by":"publisher","first-page":"299","DOI":"10.5858\/arpa.2022-0297-OA","article-title":"A Population-Based Study of Patients With Small Cell Carcinoma of the Ovary, Hypercalcemic Type, Encompassing a 30-Year Period","volume":"148","author":"Blatnik A","year":"2024","journal-title":"Arch Pathol Lab Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2015.11.004","article-title":"Small cell carcinoma of the ovary-hypercalcemic type (SCCOHT): A review of 47 cases","volume":"140","author":"Callegaro-Filho","year":"2016","journal-title":"Gynecol Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2931","article-title":"Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type","volume":"46","author":"Witkowski","year":"2014","journal-title":"Nat Genet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15153794","article-title":"Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT): Patient Characteristics, Treatment, and Outcome-A Systematic Review","volume":"15","author":"Wens","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/01.pgp.0000139644.38835.9d","article-title":"An immunohistochemical analysis of ovarian small cell carcinoma of hypercalcemic type","volume":"23","author":"McCluggage WG","year":"2004","journal-title":"Int J Gynecological Pathology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2928","article-title":"Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4","volume":"46","author":"Ramos","year":"2014","journal-title":"Nat Genet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/path.4633","article-title":"Dual loss of the SWI\/SNF complex ATPases SMARCA4\/BRG1 and SMARCA2\/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type","volume":"238","author":"Karnezis","year":"2016","journal-title":"J Pathol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3390\/cancers16173068","article-title":"Aberrant SWI\/SNF Complex Members Are Predominant in Rare Ovarian Malignancies-Therapeutic Vulnerabilities in Treatment-Resistant Subtypes","volume":"16","author":"Ma","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/path.4912","article-title":"The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type","volume":"242","author":"Wang","year":"2017","journal-title":"J Pathol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0678","article-title":"Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models","volume":"16","author":"Chan-Penebre","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30451-4","article-title":"Tazemetostat in advanced epithelioid sarcoma with loss of INI1\/SMARCB1: an international, open-label, phase 2 basket study","volume":"21","author":"Gounder","year":"2020","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/cells9061496","article-title":"Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT) beyond SMARCA4 Mutations: A Comprehensive Genomic Analysis","volume":"9","author":"Auguste","year":"2020","journal-title":"Cells"},{"key":"B16","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13048-025-01649-8","article-title":"Single-cell RNA sequencing reveals the intra-tumoral heterogeneity and immune microenvironment of small cell carcinoma of the ovary, hypercalcemic type","volume":"18","author":"Gao","year":"2025","journal-title":"J Ovarian Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcpc1000272","article-title":"Case records of the Massachusetts General Hospital. Case 8-2010. A 22-year-old woman with hypercalcemia and a pelvic mass","volume":"362","author":"Young RH","year":"2010","journal-title":"The new englnd Journal of medicine"},{"key":"B18","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/annonc\/mdy001","article-title":"Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Ray-Coquard","year":"2018","journal-title":"Ann Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1067\/j.cpradiol.2017.08.004","article-title":"Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Clinical and Imaging Review","volume":"47","author":"Korivi","year":"2018","journal-title":"Curr Probl Diagn Radiol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e39226","DOI":"10.1097\/MD.0000000000039226","article-title":"MR imaging diagnosis of small-cell carcinoma of the ovary, hypercalcemic type: A case report and literature review","volume":"103","author":"Li","year":"2024","journal-title":"Med (Baltimore)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000000293","article-title":"Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian small cell cancers","volume":"24","author":"Reed","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1999.5619","article-title":"Hypercalcemia due to parathyroid hormone-related protein produced by primary ovarian clear cell adenocarcinoma: case report","volume":"76","author":"Tsunematsu","year":"2000","journal-title":"Gynecol Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp042806","article-title":"Hypercalcemia Associated with Cancer","volume":"352","author":"Stewart","year":"2005","journal-title":"New Engl J Med"},{"key":"B24","article-title":"Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer","year":"2025","journal-title":"Natl Compr Cancer Network"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/his.12988","article-title":"Loss of SMARCA4 (BRG1) protein expression as determined by immunohistochemistry in small-cell carcinoma of the ovary, hypercalcaemic type distinguishes these tumours from their mimics","volume":"69","author":"Clarke","year":"2016","journal-title":"Histopathology"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30091-7","article-title":"ESGO-SIOPE guidelines for the management of adolescents and young adults with non-epithelial ovarian cancers","volume":"21","author":"Sessa","year":"2020","journal-title":"Lancet Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3797","article-title":"Small-Cell Carcinoma of the Ovary, Hypercalcemic Type-Genetics, New Treatment Targets, and Current Management Guidelines","volume":"26","author":"Tischkowitz","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.7150\/jca.26978","article-title":"An In-Depth Look at Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT): Clinical Implications from Recent Molecular Findings","volume":"10","author":"Lu","year":"2019","journal-title":"J Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2019.02.002","article-title":"The dilemma of early preventive oophorectomy in familial small cell carcinoma of the ovary of hypercalcemic type","volume":"28","author":"Pejovic","year":"2019","journal-title":"Gynecol Oncol Rep"},{"key":"B30","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.annonc.2022.10.004","article-title":"Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline","volume":"34","author":"Sessa","year":"2023","journal-title":"Ann Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.07.019","article-title":"Dose-intensive regimen treatment for small-cell carcinoma of the ovary of hypercalcemic type (SCCOHT)","volume":"159","author":"Blanc-Durand","year":"2020","journal-title":"Gynecol Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/IGC.0b013e3181a1a116","article-title":"Clinical management of ovarian small-cell carcinoma of the hypercalcemic type: a proposal for conservative surgery in an advanced stage of disease","volume":"19","author":"Dykgraaf","year":"2009","journal-title":"Int J Gynecol Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/s0029-7844(98)00025-8","article-title":"Uterine and ovarian conservation in advanced small cell carcinoma of the ovary","volume":"91","author":"John","year":"1998","journal-title":"Obstetrics Gynecology"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/IGC.0b013e3181a83ea2","article-title":"Aggressive small cell carcinoma of the ovary, hypercalcemic type with hypercalcemia in pregnancy, treated with conservative surgery and chemotherapy","volume":"19","author":"McCormick","year":"2009","journal-title":"Int J Gynecol Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59030544","article-title":"Ovarian Cancer-Insights into Platinum Resistance and Overcoming It","volume":"59","author":"Havasi","year":"2023","journal-title":"Medicina (Kaunas)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2005.06.051","article-title":"Lymph node metastasis in ovarian cancer: difference between serous and non-serous primary tumors","volume":"99","author":"Takeshima","year":"2005","journal-title":"Gynecol Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000001243","article-title":"Small Cell Carcinoma of the Ovary: A Rare Tumor With a Poor Prognosis","volume":"28","author":"Nasioudis","year":"2018","journal-title":"Int J Gynecol Cancer"},{"key":"B38","article-title":"Value of frozen section to tailor surgical staging in apparent early-stage epithelial ovarian cancer","volume":"101746","author":"Di Berardino","year":"2025","journal-title":"Int J Gynecol Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2005.10.024","article-title":"Small cell of the ovary, hypercalcemic type \u2013 analysis of combined experience and recommendation for management","volume":"100","author":"Harrison","year":"2006","journal-title":"A GCIG study. Gynecol Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19890915)64:6<1183::aid-cncr2820640603>3.0.co;2-n","article-title":"Vinblastine, cisplatin, cyclophosphamide, bleomycin, doxorubicin, and etoposide in the treatment of small cell carcinoma of the ovary","volume":"64","author":"Senekjian","year":"1989","journal-title":"Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm376","article-title":"Results of a prospective dose-intensive regimen in 27 patients with small cell carcinoma of the ovary of the hypercalcemic type","volume":"18","author":"Pautier","year":"2007","journal-title":"Ann Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2922","article-title":"Recurrent SMARCA4 mutations in small cell carcinoma of the ovary","volume":"46","author":"Jelinic","year":"2014","journal-title":"Nat Genet"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.916790","article-title":"Case Report: A Durable Response to Camrelizumab and Apatinib Combination Therapy in a Heavily Treated Small Cell Carcinoma of the Ovary, Hypercalcemic Type","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14184468","article-title":"Utility of the Diffusion Weighted Sequence in Gynecological Imaging: Review Article","volume":"14","author":"Bonde","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2014.12.003","article-title":"Radiotherapy for recurrent small cell carcinoma of the ovary: A case report and review of the literature","volume":"11","author":"Callegaro-Filho","year":"2015","journal-title":"Gynecol Oncol Rep"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.06.160","article-title":"Small cell carcinoma of the ovary hypercalcemic type (SCCOHT): Comprehensive management of a newly diagnosed young adult","volume":"158","author":"Pressey","year":"2020","journal-title":"Gynecol Oncol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/pbc.22285","article-title":"Age, stage, and radiotherapy, but not primary tumor site, affects the outcome of patients with malignant rhabdoid tumors","volume":"54","author":"Sultan","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2008.03495.x","article-title":"Hyperparathyroidism during pregnancy and the effect of rising calcium on pregnancy loss: a call for earlier intervention","volume":"71","author":"Norman","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B49","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1586\/14737140.4.5.889","article-title":"Impact and treatment of cancer during pregnancy","volume":"4","author":"Weisz B","year":"2004","journal-title":"Expert Rev Anticancer Ther"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.115.068593","article-title":"Hepatic Cytochrome P450 Activity, Abundance, and Expression Throughout Human Development","volume":"44","author":"Sadler","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1997.4801","article-title":"Advanced-Stage Small Cell Carcinoma of the Ovary in Pregnancy: Long-Term Survival after Surgical Debulking and Multiagent Chemotherapy","volume":"66","author":"Tewari K","year":"1997","journal-title":"Gynecologic Oncol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1006\/gyno.2001.6439","article-title":"Paclitaxel and platinum chemotherapy for ovarian carcinoma during pregnancy","volume":"83","author":"Sood","year":"2001","journal-title":"Gynecol Oncol"},{"key":"B53","doi-asserted-by":"crossref","DOI":"10.1016\/j.reprotox.2004.11.002","article-title":"Pregnancy outcome after prenatal exposure to bleomycin, etoposide and cisplatin for malignant ovarian germ cell tumors: report of 2 cases","volume":"19","author":"Han","year":"2005","journal-title":"Reprod Toxicol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1103429","article-title":"Prognosis comparison between small cell carcinoma of ovary and high-grade serous ovarian cancer: A retrospective observational cohort study","volume":"14","author":"Hu","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-011-1846-5","article-title":"Small cell carcinoma of the ovary of the hypercalcaemic type: an analysis of clinical and prognostic aspects of a rare disease on the basis of cases published in the literature","volume":"284","author":"Estel","year":"2011","journal-title":"Arch Gynecol Obstet"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1645361\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T04:10:16Z","timestamp":1755231016000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1645361\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":55,"alternative-id":["10.3389\/fonc.2025.1645361"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1645361","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,15]]},"article-number":"1645361"}}